{"id":"W2951268098","doi":"10.1136/annrheumdis-2019-eular.331","title":"SAT0157 REAL-WORLD EVALUATION OF PERSISTENCE WITH EARLY-LINE ABATACEPT VERSUS TUMOR NECROSIS FACTOR-INHIBITORS FOR RHEUMATOID ARTHRITIS COMPLICATED BY POOR PROGNOSTIC FACTORS","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Regeneron Pharmaceuticals; Celgene; Biogen; Gilead Sciences; Momenta Pharmaceuticals; Genentech; Valeant Pharmaceuticals International; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Abatacept; Medicine; Rheumatoid arthritis; Tumor necrosis factor alpha; Immunology; Rheumatoid factor; Arthritis; Oncology; Internal medicine; Antibody; Rituximab","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001330504,0.0004632675,0.001085015,0.0003406037,0.0003309317,0.0008319392,0.0003754083,0.0005664004,0.002507513],"category_scores_gemma":[0.004005095,0.0001395304,0.0009397223,0.0005161429,0.0002725285,0.0005925656,0.0003355732,0.0006366807,0.0005439677],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004353163,"about_ca_system_score_gemma":0.0004155574,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001616314,"about_ca_topic_score_gemma":0.001613902,"domain_scores_codex":[0.9993229,0.0002636533,0.00008338672,0.0001567099,0.00007952197,0.00009378864],"domain_scores_gemma":[0.9973666,0.0009878675,0.0007400903,0.0001532198,0.0003458688,0.0004062928],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1532449,0.002576791,0.7516152,0.000943327,0.003010216,0.0006153837,0.0002801967,0.002812164,0.003676377,0.0002083971,0.003881804,0.0771351],"study_design_scores_gemma":[0.004841489,0.03525725,0.9368089,0.0001745921,0.00246161,0.001539759,0.0005142718,0.0112264,0.0019641,0.000428488,0.004661835,0.0001211897],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995796,0.0007435947,0.0002275911,0.0001159213,0.000035931,0.00006389213,0.002338039,0.00002439758,0.000654672],"genre_scores_gemma":[0.9966058,0.000167908,0.0003857919,0.00007030925,0.00004637484,0.00007682912,0.002463756,0.000005332001,0.0001779524],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002507513,"threshold_uncertainty_score":0.00838846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07382460127520298,"score_gpt":0.3289128611489315,"score_spread":0.2550882598737286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}